Alzheimer; News from the web:
AstraZeneca plc (AZN – Analyst Report) and Eli Lilly and Company (LLY – Analyst Report) announced that a phase II/III study (AMARANTH) on their BACE inhibitor, AZD3293, will continue into phase III of the phase II/III seamless study. AZD3293 is being evaluated for the treatment of patients suffering from early Alzheimer’s disease – the most common form of dementia.
Read all about it HERE